Diabetes Technology Use for Management of Type 1 Diabetes Is Associated With Fewer Adverse COVID-19 Outcomes: Findings From the T1D Exchange COVID-19 Surveillance Registry

People with coronavirus disease 2019 (COVID-19) and preexisting type 1 diabetes (T1D) are at high risk of diabetes-related outcomes such as diabetic ketoacidosis (DKA) and hospitalization (1). For people with elevated glucose levels, infections could further exacerbate the risk of acute complications. As part of the management of T1D, the use of diabetes technology including continuous glucose monitors (CGM) and insulin pumps is recommended to improve glycemic control (2). However, despite increasing evidence of the benefits of diabetes technology, its uptake remains low, in part owing to systemic racism and social inequities, including in diabetes and device education, patient motivation, and peer support (3,4). The aim of this article is to examine the association of technology use and clinical outcomes during the COVID-19 pandemic.

https://diabetesjournals.org/care/article/44/8/e160/138852/Diabetes-Technology-Use-for-Management-of-Type-1